Comparison

Esculentoside A European Partner

Item no. TMO-T3877-10mg
Manufacturer TargetMol
CASRN 65497-07-6
Amount 10 mg
Quantity options 100 mg 1 mL x 10 mM (in DMSO) 10 mg 1 mg 200 mg 25 mg 2 mg 500 mg 50 mg 5 mg
Category
Type Molecules
Specific against other
Citations 1. Zhong WT,et al. Protective effect of esculentoside A on lipopolysaccharide-induced acute lung injury in mice. J Surg Res. 2013 Nov;185(1):364-72.
Smiles COC(=O)[C@@]1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@H](O)[C@H](O[C@@H]6OC[C@@H](O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O
ECLASS 10.1 32169090
ECLASS 11.0 32169090
UNSPSC 12000000
Alias NF-kappaB inhibitor
Shipping Condition Cool pack
Available
Manufacturer - Targets
NF-κB|||COX
Shipping Temperature
Cool pack
Storage Conditions
-20
Molecular Weight
826.96
Description
Esculentoside A can suppress inflammatory responses in LPS-induced ALI through inhibition of the NF-κB and mitogen-activated protein kinase signaling pathways. Esculentoside A may be useful for the treatment of autoimmune disease through modulation on T cell-mediated adaptive immunity. Esculentoside A may play significant roles in the treatment of BXSB mice through modulation of inflammatory cytokines, inhibition of renal cell proliferation and induction of apoptosis.
Pathways
NF-κB|||Immunology/Inflammation|||Neuroscience

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 10 mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close